李德山教授现任东北农业大学生命科学学院生物制药教研室主任，长期从事蛋白药物，抗体药物和基因治疗药物的研发，所研发的治疗糖尿病的"脂糖素"即将进入临床研究，所研发的治疗类风湿性关节炎、抗乙肝病毒感染等抗体药物，治疗恶性肿瘤的基因治疗药物等已完成成药性研究，正在寻求企业合作。 近年发表的代表性文章 1. F. L. Bai, H. Tian, Q. Z. Yu, G. P. Ren, and D. S. Li. Expressing Foreign Genes by Newcastle Disease Virus for Cancer Therapy. Molecular Biology. 2015, 49(2):171-178 DOI: 10.1134/S0026893315020028 ( Impact Factor: 0.74) 2. X. Ye, J. Qi, Y. Wu, D. Yu, P. Xu, S. Li, S. Zhu, Q. Wu, G. Ren, D. Li. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice. Diabetes & Metabolism. 2015, 41(1):82-90 doi:10.1016/j.diabet.2014.09.001 ( Impact Factor: 2.845) 3. Wen-fei Wang, Lei Ma, Ming-yao Liu, Ting-ting Zhao, Tong Zhang, Yong-bi Yang, Hong-xue Cao, Xiao-hui Han, De-shan Li. A novel function for fibroblast growth factor 21: stimulation of NADPH oxidase-dependent ROS generation. Endocrine, 2014 DOI 10.1007/s12020-014-0502-9 ( Impact Factor: 3.527) 4. Xianlong Ye, Jianying Qi, Guiping Ren, Pengfei Xu, Yunzhou Wu, Shenglong Zhu, Dan Yu, Shujie Li, Qiang Wu, Rasool Lubna Muhi, Deshan Li. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice. Endocrine, 2015,49（3）：683–692 DOI 10.1007/s12020-014-0503-8 ( Impact Factor: 3.527) 5. Yinhang Yu, Siming Li, Yaonan Liu, Guiyou Tian, Qingyan Yuan, Fuliang Bai, Wenfei Wang, Zhiyi Zhang, Guiping Ren, Yu Zhang, Deshan Li. Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway. International Immunopharmacology. 2015 DOI:10.1016/j.intimp.2015.01.005 ( Impact Factor: 2.711)